Imaging in evaluation of response to neoadjuvant breast cancer treatment.
作者信息
Ollivier L, Balu-Maestro C, Leclère J
机构信息
Department of Medical Imaging, Institut Curie, 26 rue d'Ulm, 75005 Paris, France.
出版信息
Cancer Imaging. 2005 May 24;5(1):27-31. doi: 10.1102/1470-7330.2005.0009.
Abstract
The role of imaging for patients treated with neoadjuvant therapy for breast cancer is not only to evaluate the therapeutic response in terms of tumour shrinkage, but also to predict the histological response to chemotherapy, which is correlated to survival. Surgery and histopathological analysis after neoadjuvant therapy allow for an objective assessment of the accuracy of imaging techniques in evaluating response. The aim of this study is to compare the value of the different conventional and functional imaging techniques for determining response to neoadjuvant chemotherapy in breast cancer treatment.
摘要
相似文献
1
Imaging in evaluation of response to neoadjuvant breast cancer treatment.
Cancer Imaging. 2005 May 24;5(1):27-31. doi: 10.1102/1470-7330.2005.0009.
2
CT findings of breast cancer with clinically complete response following neoadjuvant chemotherapy--histological correlation.
Oncol Rep. 2003 Sep-Oct;10(5):1411-5.
3
Neoadjuvant chemotherapy in stage III breast cancer.
Am Surg. 2005 Jun;71(6):487-92.
4
Breast cancer and neoadjuvant therapy: any predictive marker?
Neoplasma. 2004;51(6):471-80.
5
Diffusion-weighted imaging in evaluating the response to neoadjuvant breast cancer treatment.
Breast J. 2011 Nov-Dec;17(6):610-9. doi: 10.1111/j.1524-4741.2011.01160.x. Epub 2011 Sep 20.
6
MRI and conservative treatment of locally advanced breast cancer.
Eur J Surg Oncol. 2005 Dec;31(10):1129-34. doi: 10.1016/j.ejso.2005.03.004.
7
Neoadjuvant chemotherapy for early breast cancer.
Expert Opin Pharmacother. 2009 Jun;10(9):1423-34. doi: 10.1517/14656560903002105.
8
Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapy.
Breast Cancer Res Treat. 2005 Aug;92(3):231-8. doi: 10.1007/s10549-005-2510-1.
9
Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer.
Clin Cancer Res. 2008 Oct 15;14(20):6580-9. doi: 10.1158/1078-0432.CCR-07-4310.
10
Can diffusion-weighted MR imaging and contrast-enhanced MR imaging precisely evaluate and predict pathological response to neoadjuvant chemotherapy in patients with breast cancer?
Breast Cancer Res Treat. 2012 Aug;135(1):17-28. doi: 10.1007/s10549-012-2033-5. Epub 2012 Apr 4.
引用本文的文献
1
The Rush to Evaluate Response at the End of Treatment in Breast Cancer Patients Who Received Neoadjuvant Treatment: Which Tests are Effective in The Selection of Surgical Technique?
Asian Pac J Cancer Prev. 2025 Feb 1;26(2):619-624. doi: 10.31557/APJCP.2025.26.2.619.
2
Surgical Planning after Neoadjuvant Treatment in Breast Cancer: A Multimodality Imaging-Based Approach Focused on MRI.
Cancers (Basel). 2023 Feb 24;15(5):1439. doi: 10.3390/cancers15051439.
3
Impact of COVID-19 On Breast Cancer Management: A Radiological Prespective from A Tertiary Centre.
Eur J Breast Health. 2021 Mar 31;17(2):180-187. doi: 10.4274/ejbh.galenos.2021.6379. eCollection 2021 Apr.
4
⁹⁹mTc-3PRGD₂ SPECT to monitor early response to neoadjuvant chemotherapy in stage II and III breast cancer.
Eur J Nucl Med Mol Imaging. 2015 Aug;42(9):1362-70. doi: 10.1007/s00259-015-3062-1. Epub 2015 May 7.
5
Monitoring of tumor response to Cisplatin using optical spectroscopy.
Transl Oncol. 2014 Apr;7(2):230-9. doi: 10.1016/j.tranon.2014.02.009. Epub 2014 Mar 4.
6
99mTc-thymine scintigraphy may be a promising method in the diagnosis of breast cancer.
Clinics (Sao Paulo). 2013;68(3):283-9. doi: 10.6061/clinics/2013(03)oa01.
7
FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients.
Eur J Nucl Med Mol Imaging. 2011 Jun;38(6):1029-36. doi: 10.1007/s00259-011-1735-y. Epub 2011 Feb 10.
8
Detecting treatment response in a model of human breast adenocarcinoma using hyperpolarised [1-13C]pyruvate and [1,4-13C2]fumarate.
Br J Cancer. 2010 Oct 26;103(9):1400-6. doi: 10.1038/sj.bjc.6605945. Epub 2010 Oct 5.
9
Multiparametric monitoring of tumor response to chemotherapy by noninvasive imaging.
Cancer Res. 2009 Feb 1;69(3):1182-9. doi: 10.1158/0008-5472.CAN-08-2001. Epub 2009 Jan 13.
本文引用的文献
1
Imaging in evaluation of response to neoadjuvant breast cancer treatment benefits of MRI.
Breast Cancer Res Treat. 2002 Mar;72(2):145-52. doi: 10.1023/a:1014856713942.
2
Assessment of response by breast helical computed tomography to neoadjuvant chemotherapy in large inflammatory breast cancer.
Clin Breast Cancer. 2002 Jan;2(4):304-10. doi: 10.3816/cbc.2002.n.007.
3
Accuracy of contrast-enhanced computed tomography in the prediction of residual breast cancer after neoadjuvant chemotherapy.
Int J Cancer. 2001 Feb 20;96(1):66-73. doi: 10.1002/1097-0215(20010220)96:1<66::aid-ijc7>3.0.co;2-t.
4
Patients with breast cancer: differences in color Doppler flow and gray-scale US features of benign and malignant axillary lymph nodes.
Radiology. 2000 May;215(2):568-73. doi: 10.1148/radiology.215.2.r00ap20568.
5
Locally advanced breast carcinoma: evaluation of mammography in the prediction of residual disease after induction chemotherapy.
Anticancer Res. 2000 Jan-Feb;20(1B):553-8.
6
Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer.
J Clin Oncol. 2000 Apr;18(8):1689-95. doi: 10.1200/JCO.2000.18.8.1689.
7
Multicentric and multifocal cancer: whole-breast US in preoperative evaluation.
Radiology. 2000 Jan;214(1):59-66. doi: 10.1148/radiology.214.1.r00ja2559.
8
9
10
Zotero 插件